Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07611929

Correlation Studies on Human Body Composition Based on Bioequivalence or Pharmacokinetic Trials

The aim of this observational study is to investigate the impact of body composition on the absorption, distribution, and metabolism of drugs. The primary question it seeks to answer is: Does body composition affect the absorption, distribution, and metabolism of drugs? By combining pharmacokinetic parameters and adverse drug reactions, the study will analyze differences in the metabolism of drugs under various body composition conditions.

During the Phase I clinical trial, under the guidance of the researchers, subjects will use the non-invasive InBody S10 body composition analyzer to obtain body composition data, including but not limited to inorganic salts, muscle mass, lean body mass, body weight, and body fat percentage.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Healhty

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The Second Affiliated Hospital and Yuying Children's Hospital Affiliated to Wenzhou Medical University

Wenzhou, Zhejiang, 325802, China

Location status: Recruiting

Location contact

TING Li

CONTACT

[email protected]

0577-88002664

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants who have been successfully enrolled in the bioequivalence trials of Progesterone Sustained-release vaginal gel；
  • Have signed the informed consent form, have a full understanding of the content, process, and risks of this study, and can communicate well with the researchers.

Exclusion criteria

1:

1）Participants who may not be able to complete the study for other reasons or are deemed by the investigator to be unsuitable for participation in this study.

Treatment and study plan

Primary outcomes

  1. Fat percentage (%)

    Time frame: The day before using drug，and 1 to 4 days after using drug

    Using a body composition analyzer：Inbody S10, non-invasively obtain the subject's body composition data。This instrument applies a very small electrical current to the body and obtains data on various body components based on the characteristics of different body compositions, including fat percentage (%)

  2. Weight

    Time frame: The day before using drug，and 1 to 4 days after using drug

    Weight (kilogram) measured using a body weight scale.

Study contacts

Contact information is provided by the study sponsor or research team.

TING LI

CONTACT

[email protected]

0577-88002664

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital of Wenzhou Medical University

Other

Registry information

Important dates

Study start
2024
Primary completion
2029
Study completion
2029
First posted
May 28, 2026
Registry last updated
May 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.